# Epigenetic Basis of Stress-Induced Central Nervous System Disorders: Therapeutic Approaches

## TL;DR

This review explores how stress causes long-term changes in the brain through epigenetic and post-transcriptional mechanisms, and how these changes can be reversed to treat stress-related disorders like depression and PTSD.

## Contribution

The paper identifies specific epigenetic and post-transcriptional markers linked to stress-induced CNS disorders and highlights their potential for targeted therapeutic strategies.

## Key findings

- Chronic stress alters methylation of genes like NR3C1, FKBP5, and BDNF, linked to HPA axis dysfunction and CNS remodeling.
- Pharmacological and non-pharmacological interventions can reverse some epigenetic changes associated with stress-related disorders.
- MicroRNA profiles such as miR-16, miR-124, and miR-132 are consistently altered in stress-exposed models and clinical cohorts.

## Abstract

Stress can lead to long-term changes in the central nervous system and contribute to disorders such as depression and post-traumatic stress disorder. This review examines how epigenetic and post-transcriptional mechanisms influence the brain’s vulnerability to stress. We analyzed studies showing that chronic stress alters methylation of key stress-response genes, histone acetylation levels, and the activity of specific microRNAs. These alterations are associated with dysfunction of the hypothalamic–pituitary–adrenal axis and structural and functional remodeling of limbic and cortical brain circuits. Importantly, many of these changes are reversible: both pharmacological interventions and non-pharmacological approaches can normalize epigenetic patterns and improve outcomes. Therefore, targeted modulation of these molecular pathways provides a promising foundation for developing candidate biomarkers and informing stratified, mechanism-based prevention and treatment strategies for stress-induced central nervous system disorders.

Accumulating evidence indicates that epigenetic and post-transcriptional mechanisms interact to shape stress vulnerability and the adaptive capacity of the central nervous system (CNS). This review aimed to identify molecular markers with potential prognostic value for stress-induced CNS disorders. We analyzed 93 publications (2008–2025) identified in PubMed, Scopus, Web of Science Core Collection, and the Cochrane Library, including 80 original experimental and clinical studies, as well as 13 reviews and meta-analyses addressing epigenetic regulation, hypothalamic–pituitary–adrenal (HPA) axis function, CNS remodeling, and therapeutic or environmental modulation in stress-exposed models and clinical cohorts with stress-related disorders. Across studies, altered methylation of NR3C1, FKBP5, and BDNF, reduced hippocampal histone acetylation, and shifts in microRNA profiles (miR-16, miR-124, miR-132, miR-135a, miR-34c) were repeatedly associated with HPA axis dysregulation, limbic system remodeling, and phenotypes relevant to PTSD and depression. Evidence further suggests that at least some of these signatures show partial reversibility, with modulation reported after pharmacological interventions (e.g., SSRIs, histone deacetylase inhibitors, FKBP51 inhibitors, ketamine) and non-pharmacological approaches (e.g., physical activity, social support) in animal models and, to a lesser extent, in clinical and observational studies. We conclude that targeted modulation of specific epigenetic and post-transcriptional pathways supports the development of candidate biomarkers and may inform stratified prevention and treatment strategies for stress-induced CNS disorders, while acknowledging that further validation in large, well-characterized cohorts is required.